Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (2) , 370-380
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Eli Lilly and Company
- Novartis
- MedImmune
- School of Public Health, University of California, Berkeley
This publication has 95 references indexed in Scilit:
- Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 DiabetesPLOS ONE, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe PsoriasisJournal of Investigative Dermatology, 2012
- Highly Upregulated Expression of CD36 and MSR1 in Circulating Monocytes of Patients with Acute Coronary SyndromesThe Protein Journal, 2012
- Putting together the psoriasis puzzle: an update on developing targeted therapiesDisease Models & Mechanisms, 2012
- Chemokine receptor CCR5: from AIDS to atherosclerosisBritish Journal of Pharmacology, 2011
- Proteinase 3 and prognosis of patients with acute myocardial infarctionClinical Science, 2010
- Inflammatory biomarkers in coronary artery diseaseJournal of Cardiology, 2009
- Alopecia areata investigational assessment guidelines–Part IIJournal of the American Academy of Dermatology, 2004
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004